The impact of the COVID-19 pandemic on quality of life, physical and psychosocial wellbeing in breast cancer patients and survivors – a prospective, multicenter cohort study

Authors

Claudia A Bargon CA^{1, 2}, MD; Marilot CT Batenburg⁵, MD; Lilianne E van Stam¹; BSc, Dieuwke R Mink van der Molen¹, BSc; Iris E van Dam⁴, MD; Femke van der Leij⁴, MD, PhD; Inge O Baas⁵, MD, PhD; Miranda F Ernst⁶, MD; Wiesje Maarse³, MD, PhD; Nieke Vermulst⁷, MD; Ernst JP Schoenmaeckers⁸, MD, PhD; Thijs van Dalen⁹, MD, PhD; Rhodé M Bijlsma⁵, MD, PhD; Danny A Young-Afat¹⁰, MD, PhD; Annemiek Doeksen², PhD; Helena M Verkooijen^{1,11}, MD, PhD; UMBRELLA study group

Affiliations

¹ Division of Imaging and Oncology, University Medical Center (UMC) Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

² Department of Surgery, St. Antonius Hospital, Soestwetering 1, 3543 AZ Utrecht, The Netherlands.

³ Department of Plastic, Reconstructive and Hand surgery, University Medical Center Utrecht, Utrecht, The Netherlands.

⁴ Department of Radiation Oncology, University Medical Center Utrecht, Cancer Center, Utrecht, the Netherlands.

⁵ Department of Medical Oncology, University Medical Center Utrecht, Cancer Center, Utrecht, the Netherlands.

⁶ Department of Surgery, Alexander Monro Clinics, Bilthoven, the Netherlands.

⁷ Department of Surgery, Rivierenland Hospital, Tiel, The Netherlands.

⁸ Department of Surgery, Meander Medisch Centrum, Amersfoort, The Netherlands ⁹ Department of Surgery, Diakonessenhuis Utrecht, Utrecht, The Netherlands.

¹⁰ Department of Plastic, Reconstructive and Hand surgery, Amsterdam University

Medical Center, location VUmc, The Netherlands.

¹¹ Utrecht University (UU), Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands

Role of the funding source

The authors received no financial support for the research (including study design; data collection, analysis, interpretation of data; and writing of the report), authorship, and/ or (the decision to submit the article for) publication.

Acknowledgements

We would like to thank Janet van Dasselaar for her support with the clinical data management, and Rosalie van den Boogaard for support with IRB approval. We are greatly indebted to the Medical Ethics Committee of the UMC Utrecht for expedited ethical review of the protocol.

Corresponding Author for Publication

Prof Dr HM Verkooijen Imaging Division, University Medical Center (UMC) Utrecht Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands Email: H.M.Verkooijen@umcutrecht.nl Telephone: 0031 88 755 95 75

Corresponding Author during Submission

Drs C.A. Bargon

Department of Surgery, St. Antonius Hospital

Soestwetering 1, 3543 AZ Utrecht, The Netherlands

Email: c.bargon@antoniusziekenhuis.nl

Telephone: 0031 6 53 95 27 56

Running Head

IMPACT OF COVID-19 ON BREAST CANCER PATIENTS AND SURVIVORS

Word Count

3263 words (excluding abstract, acknowledgments, tables, figure legends, and references).

Number of figures and tables

1 figure and 4 tables.

Disclosure of relationships and activities

The authors have no conflicts of interest to disclose.

Originality of the Work

This manuscript, including related data, figures and tables, is solely the work of the authors stated, has not been published and is not under consideration for publication elsewhere.

1 ABSTRACT

2 **Purpose:** The COVID-19 pandemic and the resulting social distancing and lockdown 3 measures are having a substantial impact on daily life and medical management of 4 people with breast cancer. We evaluated to what extent these changes have affected guality of life and physical, and psychosocial wellbeing of people (being) treated for 5 6 breast cancer. 7 Methods: This study was conducted within the prospective Utrecht cohort for 8 Multiple BREast cancer intervention studies and Long-term evaluation (UMBRELLA). 9 Shortly after the implementation of COVID-19 measures, extra questionnaires were 10 sent to 1595 cohort participants, including standard UMBRELLA guality of life 11 (EORTC) questionnaires. Patient-reported outcomes (PROs) were compared to the 12 most recent PROs collected within UMBRELLA before COVID-19. The impact of COVID-19 on PROs was evaluated using mixed models analysis. 13 **Results:** In total, 1051 patients (66%) completed the questionnaires. One third (n =14 15 327, 31%) reported a higher threshold to contact their general practitioner due to 16 COVID-19. A significant deterioration in emotional functioning was observed (82-6 to 17 77.9, p < 0.001) and 505 (48%, 95% CI 45-51) patients reported moderate to severe 18 loneliness. Small significant improvements were observed in QoL, physical-, social-19 and role functioning scores. In the subgroup of 51 patients under active treatment, 20 there was a strong deterioration in social functioning (69.8 to 5.0, p = 0.03). 21 **Conclusion:** Due to COVID-19, patients (being) treated for breast cancer are less 22 likely to contact physicians, and experience a deterioration in emotional functioning. 23 Patients undergoing active treatment report a strong drop in social functioning. One 24 in two patients reports (severe) loneliness. Online applications facilitating peer

- 25 contact and e-mental health interventions could support mental health and social
- ²⁶ interaction times of total lockdown or social distancing.

27

28 Word count: 275.

29

- 30 **Keywords:** Breast Cancer; COVID-19; Corona virus; Quality of Life; Psychosocial
- 31 Wellbeing; Longitudinal; UMBRELLA; pandemic; Patient-reported outcomes.

33 ABBREVIATIONS

34	BMI	Body Mass Index
35	CF	Cognitive functioning (EORTC-QLQ30 subdomain)
36	CI	95% Confidence Interval
37	COVID-19	COronaVIrus Disease 2019
38	DCIS	Ductal carcinoma in situ
39	EF	Emotional functioning (EORTC-QLQ30 subdomain)
40	EORTC	European Organization for Research and Treatment of Cancer
41	HADS	Hospital Anxiety and Depression Scale
42	IQR	Interquartile range
43	MD	Mean Difference
44	METC	Medical Ethics Research Committee (Dutch: Medisch Ethische
45		Toetsingscommissie)
46	n	number
47	NKR	Netherlands Cancer Registry
48	PF	Physical functioning (EORTC-QLQ30 subdomain)
49	PRO(s)	Patient reported outcome(s)
50	QoL	Quality of Life
51	RF	Role functioning (EORTC-QLQ30 subdomain)
52	SD	Standard deviation

53	SF	Social functioning (EORTC-QLQ30 subdomain)
54	SPSS	Statistical Package for Social Sciences
55	STROBE	STrengthening the Reporting of OBservational studies in
56		Epidemiology
57	UMBRELLA	Utrecht cohort for Multiple BREast cancer intervention studies
58		and Long-term evaluation
59	UMCU	University Medical Center Utrecht
60	WHO	World Health Organization

62 INTRODUCTION

63	With the outbreak of the novel and rapidly spreading coronavirus disease 2019
64	(COVID-19), many extraordinary emergency measures have been taken in order to
65	prevent and control spread of the virus. ^{1,2} National restrictions varied from total
66	lockdown to targeted quarantine and social distancing. ³⁻⁵ Despite drastic efforts, the
67	World Health Organization (WHO) declared the COVID-19 outbreak officially a
68	pandemic on March 11, 2020. ⁶
69	As the COVID-19 pandemic has put health care systems under unprecedented
70	stress, urgent re-arrangements of non COVID-19 related health care has been of vital
71	importance. ^{5,7,8} A shift of tasks and responsibilities of health care personnel was
72	needed in order to keep up with the increasing pressure on the health care
73	workforce.9,10 To prioritize hospital capacity in both workforce, (intensive care) beds
74	and medical recourses for critically ill COVID-19 patients, elective care was
75	suspended as much as possible while only emergency care and semi-urgent
76	oncological procedures were continued. ^{5,11} For breast cancer, surgical procedures
77	were postponed when possible, various types of treatment (chemo- and
78	radiotherapy) were adapted, and follow-up appointments cancelled, postponed or
79	transformed into (video)calls. ^{8,12} Also, paramedical (after)care such as medical
80	rehabilitation and psychological support was scaled down to a minimum. ¹¹
81	Delays and changes in breast cancer diagnosis, treatment and follow-up protocols
82	due to COVID-19 may induce concerns about recurrence or survival. ¹² This, in
83	combination with concerns about the new viral threat in general, could impair
84	patients' mental and emotional wellbeing. ¹³ Moreover, social support is crucial for

- ⁸⁶ cancer.^{14,15} Measures of social distancing or lockdown may interfere with networks of
- support, and have a negative impact on mental health and emotional functioning.
- 88 The purpose of this study was to measure the impact of the COVID-19 pandemic on
- quality of life, physical and psychosocial functioning of women (being) treated for
- 90 breast cancer.
- 91

92 MATERIALS & METHODS

93 Study design and participants

94	The present study was conducted within the ongoing prospective multicenter Utrecht
95	cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion
96	(UMBRELLA). ^{16,17} Since 2013, the UMBRELLA cohort included patients $\geq \Box$ 18 years
97	old, who were referred from six hospitals in the Utrecht region to the Department of
98	Radiation Oncology of the University Medical Center Utrecht (UMCU), the
99	Netherlands. Inclusion criteria were histologically proven invasive breast cancer or
100	ductal carcinoma in situ (DCIS), and the ability to understand the Dutch language
101	(written and spoken). Prior to the first appointment with the radiation oncologist,
102	breast cancer patients were invited to participate in the UMBRELLA cohort.
103	Participants provided informed consent for the longitudinal collection of clinical data
104	and patient-reported outcomes (PROs) through paper or online questionnaires at
105	regular intervals during and after treatment. ¹⁶ Clinical data, including patient, tumor
106	and treatment characteristics, was provided by the Netherlands Cancer Registry
107	(NKR). PROs were collected before the start of radiation therapy (baseline), after
108	three and six months, and each six months up to ten years thereafter through self-
109	reported questionnaires. ¹⁶ The UMBRELLA study adheres to the Dutch law on
110	Medical Research Involving Human Subjects (WMO) and the Declaration of Helsinki
111	(version 2013). The study was approved by the Medical Ethics Committee of the
112	UMCU (NL52651.041.15, METC 15/165) and is registered on clinicaltrials.gov
113	(NCT02839863). This study is reported in accordance with the STrengthening the
114	Reporting of OBservational studies in Epidemiology (STROBE) statement. ¹⁸

115

116 Data collection

117	Shortly after introduction of the COVID-19 measures in the Netherlands (March 12,
118	2020), an additional COVID-19 specific online survey was sent out on the 7th of April,
119	2020, and one reminder was sent on the 15 th of April, 2020. The survey included
120	three PRO-questionnaires (the EORTC QLQ-C30/BR23, HADS and the De Jong
121	Gierveld Loneliness Scale) and a COVID-19-specific questions. The survey was
122	conducted among active UMBRELLA cohort participants who were enrolled between
123	October 2013 and April 2020 with a known email address.
124	The cancer specific Quality of Life core questionnaire (QLQ-C30) of the European
125	Organization for Research and Treatment of Cancer (EORTC) was used to assess
126	global health-related quality of life (QoL), physical functioning, role functioning,
127	cognitive functioning, emotional functioning, social functioning, dyspnea, insomnia,
128	and financial difficulties. ¹⁹ Patients' future perspective was evaluated with the breast
129	cancer specific module (QLQ-BR23). Each subscale of the EORTC questionnaires
130	includes one to five items, all measured by a 4-point Likert scale. ¹⁹ Global QoL is
131	scored on a 7-point Likert scale. ²⁰ For each subscale a summary score was
132	calculated according to the EORTC manual. ²⁰ After linear transformation to a 0 to
133	100 scale, a higher score represents a better outcome on each domain for functional
134	scales (i.e. QoL, physical-, role-, cognitive-, social-, and emotional functioning), and a
135	lower score represents better outcome for symptom scales (i.e. dyspnea, insomnia,
136	and financial difficulties). ²⁰
137	The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms
138	of anxiety and depression. ²¹ The HADS is a 14-item scale and each item has four
139	answer options. Each question scores 0 to 3 points. Patients with scores of 8 or

¹⁴⁰ higher are at risk of having anxiety or depressive disorders.²²

142Gierveld Loneliness Scale. ²³ Each item has three scoring options: "yes", "more or143less", or "no". Loneliness scores were calculated using the matching scoring144algorithm. ²⁴ Patients with scores between two and four on the 6-item scale were145considered moderately lonely, and patients with a score above four were considered146severely lonely were. ²⁴ Scores above two on each of the 3-item subscales for147emotional and social loneliness indicate emotional and/ or social loneliness. ²⁴ 148Additional questions were developed to assess presence of (symptoms resembling)149COVID-19 and the impact of COVID-19 on health care consumption and150expectations.151PROs during COVID-19 were compared to the most recent pre-COVID-19152questionnaires as obtained within UMBRELLA. We excluded patients from153comparative analyses when their most recent questionnaire was completed more154than two years before the day that the first COVID-19 patient was diagnosed in the155Netherlands (February 27, 2020).156Clinical data was obtained from the electronic patient records and from the157UMBRELLA dataset as retrieved from the NKR, and included age at cohort158enrolment, Body Mass Index (BMI, calculated with last known mean height and159weight), smoking (current, previous, no smoker), self-reported highest educational160level (no education, primary school, pre-vocational secondary vocational education,161invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment,	141	Overall, emotional, and social loneliness was assessed using the 6-item De Jong
 algorithm.²⁴ Patients with scores between two and four on the 6-item scale were considered moderately lonely, and patients with a score above four were considered severely lonely were.²⁴ Scores above two on each of the 3-item subscales for emotional and social loneliness indicate emotional and/ or social loneliness. ²⁴ Additional questions were developed to assess presence of (symptoms resembling) COVID-19 and the impact of COVID-19 on health care consumption and expectations. PROs during COVID-19 were compared to the most recent pre-COVID-19 questionnaires as obtained within UMBRELLA. We excluded patients from comparative analyses when their most recent questionnaire was completed more than two years before the day that the first COVID-19 patient was diagnosed in the Netherlands (February 27, 2020). Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, 	142	Gierveld Loneliness Scale. ²³ Each item has three scoring options: "yes", "more or
 considered moderately lonely, and patients with a score above four were considered severely lonely were.²⁴ Scores above two on each of the 3-item subscales for emotional and social loneliness indicate emotional and/ or social loneliness.²⁴ Additional questions were developed to assess presence of (symptoms resembling) COVID-19 and the impact of COVID-19 on health care consumption and expectations. PROs during COVID-19 were compared to the most recent pre-COVID-19 questionnaires as obtained within UMBRELLA. We excluded patients from comparative analyses when their most recent questionnaire was completed more than two years before the day that the first COVID-19 patient was diagnosed in the Netherlands (February 27, 2020). Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, 	143	less", or "no". Loneliness scores were calculated using the matching scoring
 severely lonely were.²⁴ Scores above two on each of the 3-item subscales for emotional and social loneliness indicate emotional and/ or social loneliness.²⁴ Additional questions were developed to assess presence of (symptoms resembling) COVID-19 and the impact of COVID-19 on health care consumption and expectations. PROs during COVID-19 were compared to the most recent pre-COVID-19 questionnaires as obtained within UMBRELLA. We excluded patients from comparative analyses when their most recent questionnaire was completed more than two years before the day that the first COVID-19 patient was diagnosed in the Netherlands (February 27, 2020). Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, 	144	algorithm. ²⁴ Patients with scores between two and four on the 6-item scale were
 emotional and social loneliness indicate emotional and/ or social loneliness. ²⁴ Additional questions were developed to assess presence of (symptoms resembling) COVID-19 and the impact of COVID-19 on health care consumption and expectations. PROs during COVID-19 were compared to the most recent pre-COVID-19 questionnaires as obtained within UMBRELLA. We excluded patients from comparative analyses when their most recent questionnaire was completed more than two years before the day that the first COVID-19 patient was diagnosed in the Netherlands (February 27, 2020). Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	145	considered moderately lonely, and patients with a score above four were considered
148Additional questions were developed to assess presence of (symptoms resembling)149COVID-19 and the impact of COVID-19 on health care consumption and150expectations.151PROs during COVID-19 were compared to the most recent pre-COVID-19152questionnaires as obtained within UMBRELLA. We excluded patients from153comparative analyses when their most recent questionnaire was completed more154than two years before the day that the first COVID-19 patient was diagnosed in the155Netherlands (February 27, 2020).156Clinical data was obtained from the electronic patient records and from the157UMBRELLA dataset as retrieved from the NKR, and included age at cohort158enrolment, Body Mass Index (BMI, calculated with last known mean height and159weight), smoking (current, previous, no smoker), self-reported highest educational160level (no education, primary school, pre-vocational secondary education, senior161general or pre-university secondary education, secondary vocational education,162higher professional education, or university degree), surgical treatment, most163invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment,164currently receiving active treatment, pathological T and N stage (American Joint	146	severely lonely were. ²⁴ Scores above two on each of the 3-item subscales for
 COVID-19 and the impact of COVID-19 on health care consumption and expectations. PROs during COVID-19 were compared to the most recent pre-COVID-19 questionnaires as obtained within UMBRELLA. We excluded patients from comparative analyses when their most recent questionnaire was completed more than two years before the day that the first COVID-19 patient was diagnosed in the Netherlands (February 27, 2020). Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	147	emotional and social loneliness indicate emotional and/ or social loneliness. ²⁴
 expectations. PROs during COVID-19 were compared to the most recent pre-COVID-19 questionnaires as obtained within UMBRELLA. We excluded patients from comparative analyses when their most recent questionnaire was completed more than two years before the day that the first COVID-19 patient was diagnosed in the Netherlands (February 27, 2020). Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	148	Additional questions were developed to assess presence of (symptoms resembling)
 PROs during COVID-19 were compared to the most recent pre-COVID-19 questionnaires as obtained within UMBRELLA. We excluded patients from comparative analyses when their most recent questionnaire was completed more than two years before the day that the first COVID-19 patient was diagnosed in the Netherlands (February 27, 2020). Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	149	COVID-19 and the impact of COVID-19 on health care consumption and
152questionnaires as obtained within UMBRELLA. We excluded patients from153comparative analyses when their most recent questionnaire was completed more154than two years before the day that the first COVID-19 patient was diagnosed in the155Netherlands (February 27, 2020).156Clinical data was obtained from the electronic patient records and from the157UMBRELLA dataset as retrieved from the NKR, and included age at cohort158enrolment, Body Mass Index (BMI, calculated with last known mean height and159weight), smoking (current, previous, no smoker), self-reported highest educational160level (no education, primary school, pre-vocational secondary education, senior161general or pre-university secondary education, secondary vocational education,162higher professional education, or university degree), surgical treatment, most163invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment,164currently receiving active treatment, pathological T and N stage (American Joint	150	expectations.
 comparative analyses when their most recent questionnaire was completed more than two years before the day that the first COVID-19 patient was diagnosed in the Netherlands (February 27, 2020). Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	151	PROs during COVID-19 were compared to the most recent pre-COVID-19
 than two years before the day that the first COVID-19 patient was diagnosed in the Netherlands (February 27, 2020). Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	152	questionnaires as obtained within UMBRELLA. We excluded patients from
 Netherlands (February 27, 2020). Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	153	comparative analyses when their most recent questionnaire was completed more
 Clinical data was obtained from the electronic patient records and from the UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	154	than two years before the day that the first COVID-19 patient was diagnosed in the
 UMBRELLA dataset as retrieved from the NKR, and included age at cohort enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	155	Netherlands (February 27, 2020).
 enrolment, Body Mass Index (BMI, calculated with last known mean height and weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	156	Clinical data was obtained from the electronic patient records and from the
 weight), smoking (current, previous, no smoker), self-reported highest educational level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	157	UMBRELLA dataset as retrieved from the NKR, and included age at cohort
 level (no education, primary school, pre-vocational secondary education, senior general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	158	enrolment, Body Mass Index (BMI, calculated with last known mean height and
 general or pre-university secondary education, secondary vocational education, higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	159	weight), smoking (current, previous, no smoker), self-reported highest educational
 higher professional education, or university degree), surgical treatment, most invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	160	level (no education, primary school, pre-vocational secondary education, senior
 invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment, currently receiving active treatment, pathological T and N stage (American Joint 	161	general or pre-university secondary education, secondary vocational education,
164 currently receiving active treatment, pathological T and N stage (American Joint	162	higher professional education, or university degree), surgical treatment, most
	163	invasive axillary treatment, (neo)-adjuvant radiation therapy and systemic treatment,
165 Committee on Cancer [AJCC] 7 th edition).	164	currently receiving active treatment, pathological T and N stage (American Joint
	165	Committee on Cancer [AJCC] 7 th edition).

166

167 **Treatment protocols**

168	All UMBRELLA	narticinante.	undarwant	maetactom	/ or broact	CONCONVING	SURGORV
100		Januonanio	UNDERVEN	masiculum	i or prease		Suluciv
	-						

169 combined with axillary staging and/or radiotherapy. Before the COVID-19 pandemic,

all patients were treated in adherence to the Dutch guidelines for breast cancer

171 treatment, as appropriate.²⁵

172 After the start of the COVID-19 pandemic, modifications to breast cancer treatment

173 protocols were advised by the Dutch Society for Surgical Oncology (NVCO; March

174 27, 2020), and the Dutch Society for Medical Oncology (NVMO; March 22, 2020). In

general, this advice included deferring of surgery in low risk patients, and de-

escalation of (neo)adjuvant chemotherapy. Details are presented in Appendix 1.

177 Breast cancer physicians from each of the six referring hospitals (where participants

received all breast cancer treatment, except radiotherapy) confirmed to adhere to the

new national advice, with the exception of one hospital, which was exclusively

reserved for non-COVID-19 care and could therefore continue with standard surgical

181 care without any alterations, while adhering to the new advice regarding medical

182 oncological care and breast reconstructive surgery.

183

184 Statistical analysis

Frequencies, proportions, and means with standard deviations (SD) or medians with interquartile ranges (IQR) as appropriate, were used to describe patient and clinical characteristics, COVID-19 related questions, and PROs.

To measure the impact of COVID-19 on PROs, most recent reported scores from the
EORTC-QLQ30/BR23 and the HADS before the start of the COVID-19 pandemic
were compared to the PROs during COVID-19. Crude mean EORTC scores were
compared with the paired samples t-test and crude median HADS scores with the
Wilcoxon signed rank test.
To estimate whether the impact of COVID-19 on clinically relevant PROs varied with
time since (active) treatment, participants were categorized into four groups, i.e.

active treatment, non-active treatment and enrolled in UMBRELLA < 24 months

before the survey, non-active treatment and enrolled 24-60 months before the

197 survey, and non-active treatment and enrolled > 60 months before the survey. A

198 linear mixed effect model for repeated measurements was used to measure the

impact of COVID-19 on PROs, and included a patient-specific random intercept, a

200 linear time effect, and an interaction between time since diagnosis and period (pre-

201 /post-COVID-19). To correct for potential confounders, age (linear) was included as

fixed variable in the model in the non-actively treated group. In the actively treated

203 group further adjustment was performed for chemotherapy, type of radiotherapy, and

type of surgery. Changes in PROs due to COVID-19 were reported as mean

205 differences (MD) with 95% confidence intervals (CI).

All reported p-values were two-sided and p-values < 0.05 were considered

207 statistically significant. Statistical analyses were performed with the use of IBM

208 Statistical Package for Social Sciences (SPSS) software, version 25 (IBM Corp,

209 Armonk, NY).

210 **RESULTS**

- Between October 2013 and April 2020, 3239 patients were enrolled in the
- 212 UMBRELLA cohort (Fig. 1). Of all study participants, 1595 met the inclusion criteria
- for the present study and were sent the extra COVID-19 survey, of whom 1051
- 214 patients (66%) responded. Mean age was 56 years (SD 9.8) and median time since
- diagnosis was 24 months (IQR 6-42, Table 1). Most patients (56%) were treated for a
- stage 1 tumor and received breast conserving surgery (77%). Fifty-one participants
- 217 (4.9%) were receiving active treatment (chemo- and/or radiotherapy) for their breast
- cancer during the COVID-19 pandemic (Table 2).
- 219

220 Physical and psychosocial wellbeing during COVID-19

- 221 Of all responders, one patient (0.1%) had confirmed COVID-19 infection and 100
- patients (9.5%) indicated to have been possibly infected as they experienced
- symptoms of fever, but they had not been tested for the virus. Twenty-seven percent
- 224 (n = 286) of all responders felt that the COVID-19 measures affected their current
- treatment or (after)care, and 24% (n = 250) felt that these measures were likely to
- affect their (after)care in the future (Table 2).

Almost one third (n = 327, 31%) reported a higher threshold to contact their general practitioner due to the COVID-19 outbreak, and 162 patients (15%) indicated to be less likely to contact the physician treating their breast cancer. Family and friends were contacted less easily by 87 responders (8%). Most responders (n = 983, 95%) were not or a little bit worried about their financial situation as a result of COVID-19 (Table 2).

233	During the COVID-19 pandemic, 409 of all responders (39%) reported moderate
234	feelings of loneliness, and 96 (9.3%) felt severely lonely (Table 3). Of these, 202
235	patients (40%) felt socially lonely, and 396 patients (78.4%) felt emotionally lonely.
236	
237	Comparison of PROs before and during COVID-19
238	For 1022 responders (97%) pre and post COVID-19 EORTC scores, and for 942
239	(90%) pre and post COVID-19 HADS scores could be compared. Overall, mean
240	scores for the EORTC subdomains QoL, physical functioning, role functioning,
241	significantly improved during COVID-19. Mean scores for the EORTC subdomain
242	emotional functioning worsened significantly. Also, median HADS total score and
243	depression score deteriorated significantly during COVID-19 (Table 3).
244	In the subgroup of actively treated patients, there was a strong significant drop in
245	social functioning of 15.9 points during COVID-19 after adjustment for age,
246	chemotherapy, type of radiotherapy and type of surgery in mixed model analysis
247	(Table 4).
248	Among the non-actively treated patients, age adjusted analyses showed that
249	emotional functioning worsened significantly in all groups, whereas physical
250	functioning improved significantly in all groups (Table 4). QoL, role functioning, and
251	social functioning improved significantly in non-actively treated patients who were

enrolled in UMBRELLA < 24 months (Table 4).

253

254 DISCUSSION

255	The COVID-19 pandemic has a substantial impact on individuals (being) treated for
256	breast cancer. One in three patients reported to be less likely to contact their general
257	practitioner, and 15% indicated to be less likely to contact their breast cancer
258	physician due to barriers induced by COVID-19 restrictions. In patients actively
259	receiving treatment, social functioning decreased dramatically, and in patients who
260	were no longer receiving active treatment, deterioration of emotional functioning was
261	observed. At the same time, COVID-19 seemed to have a positive effect on QoL,
262	physical functioning, role functioning and social functioning in non-actively treated
263	patients. Loneliness was reported by almost 50% of all participants.
264	The high proportion of participants indicating to experience a higher barrier to contact
265	their health care providers is in line with the upsetting findings of the Dutch
266	nationwide cancer registry (NKR), who reported a nationwide decrease up to 40% in
267	cancer diagnoses during COVID-19.26 Jones and colleagues27 from the United
268	Kingdom also expressed their concerns about patients potentially feeling a higher
269	barrier to consult a general practitioner for non-specific symptoms and for moral
270	arguments. ¹² Moreover, an average drop of 37% of referrals by general practitioners
271	to all medical specialties was observed in the Netherlands during the outbreak. ²⁸ This
272	highlights the importance of creating public awareness about the risk a potential
273	delay in seeking medical help could cause, aiming to lower the barriers for patients to
274	contact a physician when they experience symptoms. ²⁶
275	Among patients who were receiving active breast cancer treatment during the
276	COVID-19 pandemic, a major decrease in social functioning was observed (Table 4).
277	One explanation for this decrease could be that these patients were more careful
278	regarding social interaction. Recent publications underlining the risk of COVID-19

related adverse events in cancer patients might have amplified their concerns about
 contracting the virus.^{8,12,29-31}

281 All non-actively treated patients (i.e., including all lengths of follow-up since 282 diagnosis) showed a significant reduction in the emotional functioning domain. The 4-283 item emotional functioning domain assesses anxiety, depression and general distress through questions about feeling tense, worrying, depressive, and irritable feelings.³² 284 285 The reduction in this domain is very likely attributable to COVID-19, since we know 286 from pre-COVID-19 work in UMBRELLA that emotional functioning of people treated 287 for breast cancer continues to increase over time (as shown in their supplementary data).³³ Also, the median score for depression worsened significantly during COVID-288 19. Concerns about the new viral threat might have enhanced overall uncertainty in 289 290 individuals. Different types of coping mechanisms could play a role here; lower 291 tolerance of uncertainty is related to higher appraisal of a health threat and higher levels emotion-focused coping strategies.¹³ A previous study showed that, during the 292 293 2009 H1N1 viral outbreak, emotion-focused coping was related with increased levels of depression.¹³ 294

295 Interestingly, despite the deterioration in emotional functioning in all non-actively 296 treated patients, there was a significant increase in global QoL, role functioning, 297 social functioning, and physical functioning. This may partly be explained by the fact that these scores tend to increase over time since diagnosis and, also in the absence 298 of COVID-19, we would expect an increase in these domains.³³ Another explanation 299 300 could be found in an effect of a Dutch media campaign that encourages (non-risk) 301 exercise to enhance both public physical and mental wellbeing in these exceptional times.³⁴ The remarkable, perhaps counter-intuitive, increase in QoL could be 302 303 explained by the fact that a shared crisis may put patients' perceived QoL in relation

304 to their disease in a different perspective, and may even accelerate reconceptualization of their QoL.³⁵ The significant increase in social and role 305 306 functioning suggests that patients reported an increased ability to fulfil responsibilities 307 associated with occupational, and/ or family roles. Governmental measures 308 encouraging work from home and prohibiting social events (i.e., less social 309 obligations) in times of social distancing or lockdown may also play a role. 310 The current study showed that 48% of all responders felt lonely, the majority 311 reporting to feel emotionally lonely. Experiencing health problems can induce Ioneliness and vice versa.³⁶ Therefore, (breast) cancer patients might be particularly 312 313 vulnerable for feelings of loneliness. Social isolation measures to fight the COVID-19 314 pandemic might enhance these feelings. Unfortunately, loneliness is not a parameter 315 that was captured routinely in the UMBRELLA cohort, so it was impossible to 316 measure the impact of COVID-19 on loneliness. However, the reported proportion of 317 48% loneliness is substantially higher than the reported 34% in the general Dutch 318 population in 2019 (pre COVID-19), as measured by the same Loneliness scale in a survey conducted by Statistics Netherlands (CBS, n = 7.398).³⁷ Also, our proportion 319 320 of patients feeling lonely was substantially higher than the 30-35% cancer patients reporting to feel lonely in a study that was conducted before COVID-19.³⁸ Moreover. 321 322 the percentage of patients feeling severely lonely was strikingly high in this study 323 when compared to other studies; almost 10% compared to 0-2% in other studies performed among cancer patients.³⁶ Thus, even though we cannot rule out other 324 325 contributing factors, the higher proportion of patients feeling lonely in this study is likely due to the COVID-19 measures. 326

With the high survival rates of breast cancer patients, mental health has become an integral focus of supportive treatment. However, a barrier to e-mental health still

exists.^{10,39} Especially in times when face-to-face contact is not an option, and when 329 330 the global need for psychological and/ or peer support is rising due to the viral threat, 331 efforts are needed to rapidly implement e-mental health programs and digital 332 psychological interventions. Only by adapting to the new circumstances will we be 333 able to treat both ongoing and emerging mental health care conditions due to COVID-19, and prevent long-term problems.^{10,40} The results of this study underline 334 335 the magnitude of the impact of a major health crisis on the psychosocial wellbeing of breast cancer patients. Considering that a second wave of COVID-19 or another 336 future outbreak with similar impact is probable,^{12,41} one would hope that the current 337 338 COVID-19 pandemic may serve as a turning point in the adoption and acceptance of successful e-mental health applications.³⁹ 339 340 A limitation of this study is the fact that only 51 patients (4.9%) in our cohort received 341 active treatment during COVID-19, causing relatively wide 95% confidence intervals 342 in this group. As a consequence, the results of this study are predominantly 343 influenced by the large group of breast cancer survivors, while the impact of COVID-344 19 might be more severe for newly diagnosed patients who, for example, 345 experienced adjusted treatment protocols such as deferred surgery. Second, even 346 though baseline characteristics of responders and non-responders were comparable, 347 an under- or overestimation of the results due to selective (non-)response could not 348 be ruled out as the reasons for 34% non-response were unclear. Third, this study 349 measured the impact of COVID-19 approximately six weeks after the start of COVID-350 19. Therefore, it is unclear whether the results of this study represent a short-term, or 351 a longer-lasting effect. However, previous literature on the 2009 H1N1 viral threat 352 showed that the psychological effects can persist up to 30 months after the

outbreak.¹³ Last, in this study, we could not compare the impact of COVID-19 on

- 354 patients (being) treated for breast cancer to the impact on a healthy reference
- 355 population. An important strength of this study is that the UMBRELLA cohort provided
- a unique opportunity to longitudinally compare validated PRO scores during COVID-
- 19 with the scores before COVID-19 in an identical population, in a representative
- 358 population of patients with breast cancer.²⁰

360 CONCLUSION

- 361 COVID-19 is having a substantial impact on individuals (being) treated for breast
- 362 cancer. Emotional functioning deteriorated in patients treated for breast cancer
- following the COVID-19 pandemic, one in two responders reported (severe)
- ³⁶⁴ loneliness, and one in three reported to be less likely to contact their health care
- ³⁶⁵ providers. In actively treated patients, social functioning decreased dramatically.
- 366 COVID-19 seemed to have a small but significant positive effect on QoL, physical
- ³⁶⁷ functioning, social functioning, and role functioning in previously treated breast
- 368 cancer patients.

370 Compliance with ethical standards

371 Conflict of interest: The authors declare no conflict of interest.

372

- 373 *Ethical approval:* This study was in accordance with the ethical standards of the
- institutional and/ or national research committee and with the 1964 Helsinki

375 declaration and its later amendments or comparable ethical standards.

376

377 Informed consent: Informed consent from all individual participants was obtained

378 within the UMBRELLA cohort.

379

380 Author contributions

381 The corresponding author (HM Verkooijen) confirms that she had full access to all the

data in the study and had final responsibility for the decision to submit for publication.

Each author has contributed significantly to, and is willing to take public responsibility

384 for, the following aspects of the study:

385	-	Design: C.A. Bargon, M.C.T. Batenburg, L.E. van Stam, D.R. Mink van der
386		Molen, W. Maarse, N. Vermulst, I.E. van Dam, F. van der Leij, E.J.P.
387		Schoenmaeckers, M.F. Ernst, I.O. Baas, T. van Dalen, R. Bijlsma, D.A.
388		Young-Afat, A. Doeksen, H.M. Verkooijen.
389	-	Data Acquisition: C.A. Bargon, M.C.T. Batenburg, L.E. van Stam, D.R. Mink
390		van der Molen, A. Doeksen, H.M. Verkooijen.

- Analyses: C.A. Bargon, M.C.T. Batenburg, L.E. van Stam, D.R. Mink van der
- 392 Molen, D.A. Young-Afat, H.M. Verkooijen.
- Interpretation C.A. Bargon, M.C.T. Batenburg, D.R. Mink van der Molen, D.A.
- 394 Young-Afat, H.M. Verkooijen.
- 395 Drafting: C.A. Bargon, L.E. van Stam,
- *Critical Revision*: C.A. Bargon, M.C.T. Batenburg, L.E. van Stam, D.R. Mink
- 397 van der Molen, W. Maarse, N. Vermulst, I.E. van Dam, F. van der Leij, E.J.P.
- 398 Schoenmaeckers, M.F. Ernst, I.O. Baas, T. van Dalen, R. Bijlsma, D.A.
- 399 Young-Afat, A. Doeksen, H.M. Verkooijen.
- 400
- 401 *Role of medical writer or editor:* The authors did not receive any writing assistance.

403 **REFERENCES**

- Wang H, Zhang L. Risk of COVID-19 for patients with cancer. *Lancet Oncol.* 2020
 Apr;21(4):**e181**. DOI: 10.1016/S1470-2045(20)30149-2.
- 406 2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
- 407 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;
- 408 **395**(10229):1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.
- 409
 3.
 Haffajee RL, Mello MM. Thinking Globally, Acting Locally The U.S. Response to
- 410 Covid-19. *N Engl J Med.* 2020 Apr 2. DOI: 10.1056/NEJMp2006740.
- 411 4. Studdert DM, Hall MA. Disease Control, Civil Liberties, and Mass Testing Calibrating
- 412 Restrictions during the Covid-19 Pandemic. *N Engl J Med.* 2020 Apr 9. DOI: 10.1056/NEJMp2007637.
- 413 5. Abu Hilal M, Besselink MG, Lemmers DHL, Taylor MA, Triboldi A. Early look at the
- future of healthcare during the COVID-19 pandemic. Br J Surg. 2020 May 8. DOI: 10.1002/bjs.11666.
- 415 6. World Health Organization (WHO). WHO Director-General's opening remarks at the
 416 media briefing on COVID-19 11 March 2020. Retreived from:
- 417 https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-
- 418 on-covid-19---11-march-2020. Published 2020. Updated March 11, 2020. Accessed April 10, 2020.
- 419 7. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources
 420 in the Time of Covid-19. N Engl J Med. 2020 Mar 23. DOI: 10.1056/NEJMsb2005114.
- 421 8. Marandino L, Necchi A, Aglietta M, et al. COVID-19 Emergency and the Need to
- 422 Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice. JCO
- 423 Oncology Practice. 0:OP.20.00237
- 424 9. Fraher EP, Pittman P, Frogner BK, et al. Ensuring and Sustaining a Pandemic
- 425 Workforce. *N Engl J Med.* 2020 Apr 8. DOI: 10.1056/NEJMp2006376.
- Liu R, Sundaresan T, Reed ME, et al. Telehealth in Oncology During the COVID-19
 Outbreak: Bringing the House Call Back Virtually. JCO Oncology Practice. 0:OP.20.00199
- 428 11. The Lancet Oncology. COVID-19: global consequences for oncology. *Lancet Oncol.*
- 429 2020 Apr;**21**(4):467. DOI: 10.1016/S1470-2045(20)30175-3.
- 430 12. The Lancet Oncology. Safeguarding cancer care in a post-COVID-19 world. *Lancet* 431 Oncol. 2020 May;**21**(5):603. DOI: 10.1016/S1470-2045(20)30243-6.

432 13. Taha S, Matheson K, Cronin T, Anisman H. Intolerance of uncertainty, appraisals, 433 coping, and anxiety: the case of the 2009 H1N1 pandemic. Br J Health Psychol. 2014 Sep; 19(3):592-434 605. DOI: 10.1111/bjhp.12058. 435 14. Sowa M, Głowacka-Mrotek I, Monastyrska E, et al. Assessment of quality of life in 436 women five years after breast cancer surgery, members of Breast Cancer Self-Help Groups - non-437 randomized, cross-sectional study. Contemp Oncol (Pozn). 2018;22(1):20-26. DOI: 438 10.5114/wo.2018.74389. 439 15. Legg MA-O, Hyde MK, Occhipinti S, Youl PH, Dunn J, Chambers SK. A prospective 440 and population-based inquiry on the use and acceptability of peer support for women newly diagnosed 441 with breast cancer. Support Care Cancer. 2019 Feb;27(2):677-685. DOI: 10.1007/s00520-018-4358-z. 442 16. Young-Afat DA, van Gils CH, van den Bongard H, Verkooijen HM. The Utrecht cohort 443 for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, 444 design, and baseline results. Breast Cancer Res Treat. 2017 Jul;164(2):445-450. DOI: 445 10.1007/s10549-017-4242-4. 446 17. Gal R, Monninkhof EM, van Gils CH, et al. The Trials within Cohorts design faced 447 methodological advantages and disadvantages in the exercise oncology setting. J Clin Epidemiol. 448 2019 Sep;**113**:137–146. DOI: 10.1016/j.jclinepi.2019.05.017. 449 18. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of 450 Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational 451 studies. J Clin Epidemiol. 2008 Apr;61(4):344-9. DOI: 10.1016/j.jclinepi.2007.11.008. 452 19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, et al. The European 453 Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in 454 international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. 455 20. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC 456 QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of 457 Cancer, 2001. 458 21. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A 459 validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch 460 subjects. Psychol Med. 1997 Mar; 27(2):363-70.

461 22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr

462 *Scand.* 1983 Jun;**67**(6):361–70.

- 463 23. de Jong Gierveld J, van Tilburg T. [A shortened scale for overall, emotional and social
 464 loneliness]. *Tijdschr Gerontol Geriatr.* 2008 Feb;**39**(1):4–15.
- 465 24. de Jong Gierveld, J, van Tilburg TG. Manual of the loneliness scale. VU University
- 466 Amsterdam, Department of Social Research Methodology. Updated from the printed version: 12-11-
- 467 2019. Retreived from: https://home.fsw.vu.nl/tg.van.tilburg/manual_loneliness_scale_1999.html.
- 468 Published 2019. Accessed May 2, 2020.
- 469 25. Nationaal Borstkankeroverleg Nederland (NABON). [Landelijke richtlijn
- 470 Mammacarcinoom]. Retreived from: https://heelkunde.nl/sites/heelkunde.nl/files/richtlijnen-

471 <u>definitief/Mammacarcinoom2012.pdf</u>. Published 2012. Accessed April 20, 2020.

- 472 26. Dinmohamed AG, Visser O, Verhoeven RHA, et al. Fewer cancer diagnoses during
- 473 the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020 Apr 30. DOI: 10.1016/S1470-
- 474 2045(20)30265-5.
- 475 27. Jones D, Neal RD, Duffy SRG, Scott SE, Whitaker KL, Brain K. Impact of the COVID-
- 476 19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. *Lancet Oncol.* 2020
- 477 Apr 30. DOI: 10.1016/S1470-2045(20)30242-4.
- 478 28. ZorgDomein. [ZorgDomein heeft actuele cijfers over zorgbehandelingen die zich
- 479 opstapelen door corona crisis]. Retreived from: https://zorgdomein.com/nieuws/actuele-cijfers-
- 480 <u>uitgestelde-zorg-coronavirus/</u>. Published 2020. Accessed May 13th, 2020.
- 481 29. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a
- 482 nationwide analysis in China. Lancet Oncol. 2020 Mar;21(3):335–337. DOI: 10.1016/S1470-
- 483 2045(20)30096-6.
- 484 30. Sahu KK, Jindal V, Siddiqui AD. Managing COVID-19 in Patients With Cancer: A
- 485 Double Blow for Oncologists. JCO Oncology Practice. 16:223-225, 2020
- 486 31. Jazieh A-R, Alenazi TH, Alhejazi A, et al. Outcome of Oncology Patients Infected With
- 487 Coronavirus. JCO Global Oncology. 471-475, 2020.
- 488 32. Gamper EM, Groenvold M, Petersen MA, et al. The EORTC emotional functioning
- 489 computerized adaptive test: phases I-III of a cross-cultural item bank development. Psychooncology.
- 490 2014 Apr;**23**(4):397–403. DOI: 10.1002/pon.3427.

491	33.	Gregorowitsch ML, van den Bongard HJGD, Young-Afat DA, et al. Severe depression
492	more common	in patients with ductal carcinoma in situ than early-stage invasive breast cancer
493	patients. Breas	st Cancer Res Treat. 2018 Jan; 167 (1):205–213. DOI: 10.1007/s10549-017-4495-y.
494	34.	NOC*NCF. [EXERCISE ADVICE in times of Corona] (Dutch: SPORT- EN
495	BEWEEGADV	IEZEN in tijden van corona). Retreived from: https://nocnsf.nl/media/2521/sport-en-
496	beweegtips-in-	tijden-van-het-coronavirus.pdf. Published 2020. Accessed May 13th, 2020.
497	35.	Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of
498	life research: a	theoretical model. Soc Sci Med. 1999 Jun;48(11):1507–15.
499	36.	Deckx L, van den Akker M, Buntinx F. Risk factors for loneliness in patients with
500	cancer: a syste	ematic literature review and meta-analysis. Eur J Oncol Nurs. 2014 Oct;18(5):466-77.
501	DOI: 10.1016/j	.ejon.2014.05.002.
502	37.	Statistics Netherlands (CBS). Nearly 1 in 10 Dutch people frequently lonely in 2019.
503	Retreived from	: https://www.cbs.nl/en-gb/news/2020/13/nearly-1-in-10-dutch-people-frequently-lonely-
504	in-2019. Publis	shed 2020. Updated March 27th, 2020. Accessed May 13th, 2020.
505	38.	Deckx L, van den Akker M, van Driel M, et al. Loneliness in patients with cancer: the
506	first year after	cancer diagnosis. Psychooncology. 2015 Nov;24(11):1521–8. DOI: 10.1002/pon.3818.
507	39.	Wind TR, Rijkeboer M, Andersson G, Riper H. The COVID-19 pandemic: The 'black
508	swan' for ment	al health care and a turning point for e-health. Internet Interv. 2020 Apr 20:100317. DOI:
509	10.1016/j.inver	nt.2020.100317.
510	40.	Torales J, O'Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19
511	coronavirus an	d its impact on global mental health. Int J Soc Psychiatry. 2020 Mar;
512	31 :207640209	15212. DOI: 10.1177/0020764020915212.
513	41.	Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity
514	in China outsic	le Hubei after control measures, and second-wave scenario planning: a modelling
515	impact assess	ment. <i>Lancet.</i> 2020 Apr 25; 395 (10233):1382–1393. DOI: 10.1016/S0140-
516	6736(20)30746	6-7.
517	42.	Dutch Society of Surgical Oncology (NVCO). [Handvat voor chirurgische ingrepen
518	tijdens Corona	-crisis]. Retreived from: https://heelkunde.nl/nieuws/handvat-voor-chirurgische-
519	ingrepen-tijder	ns-corona-crisis. Published 2020. Accessed May 13th, 2020.

520

521 **APPENDIX 1**

- 522 The following (summarized) advice regarding surgical breast cancer treatment was
- ⁵²³ published by the Dutch Society for Surgical Oncology (NVCO) and the Dutch Society
- ⁵²⁴ for Gastrointestinal Surgery (NVGIC) on March 27, 2020.⁴²
- 525

526 General advice:

- 527 1. Based on foreign experiences with COVID-19 patients, sometimes
- asymptomatic patients appeared to suffer from severe pneumonia.
- 529 Therefore, one could consider to perform a CT-scan of the thorax shortly
- before the scheduled surgery in all patients who need intraoperative

531 intubation.

532

533 Breast cancer specific advice:

534	1.	Triple negative patients with locally advanced breast cancer who show little
535		response to neo-adjuvant chemotherapy (NAC) should be operated with
536		priority.

Surgery should be postponed on the short-term for patients with Her2Neu
 positive patients with a good response to NAC and who still receive
 monotherapy with trastuzumab, as well as surgery for hormone receptor
 positive (HR+) patients without progression under NAC who can already
 start with hormone therapy (HT).

- 542 3. Surgery for patients with only ductal carcinoma in situ (DCIS) and for HR+
- 543 patients who can start with HT in the waiting time to their surgery should be

544 postponed for the long-term.

- 4. It should be considered to perform surgery on patients with positive lymph
- 546 node(s) (N+) and/ or smaller tumors in order to enable postponement of
- 547 chemotherapy.

549 TABLES

- 550
- 551 Table 1. Baseline characteristics of responders and non-responders of the COVID-19 specific online
- 552 survey that was sent to active UMBRELLA breast cancer cohort participants who were enrolled
- 553 between October 2013 and April 2020.
- 554

	Respo (n = 1	nders 051, 66%)	Non- responders (n = 544, 34%)		
Patient characteristics	n	%	n	%	
Age [mean (SD]	56	(9.8)	55	(10.4)	
Gender [n, %]					
Female	1045	(99-4)	542	(99.6)	
Male	6	(0.6)	2	(0.4)	
Body Mass Index (Kg/m ²) ¹ [mean (SD)]	26.2	(4.7)	26.2	(5.0)	
Missing [n, %]	16	(1.5)	54	(9.9)	
Smoking [n, %]					
Smoker	48	(4.6)	38	(7.0)	
Previous smoker	531	(50-5)	242	(44.5)	
Non-smoker	461	(43.9)	217	(39.9)	
Unknown	11	(1.0)	47	(8.6)	
Highest educational level [n, %]					
No education	6	(0.6)	2	(0.4)	
Primary school	9	(0.9)	7	(1.3)	
Pre-vocational secondary education	134	(12.7)	64	(11.8)	
Senior general or pre-university secondary education	82	(7.8)	40	(7.4)	
Secondary vocational education	228	(21.7)	139	(25.6)	
Higher professional education	374	(35.6)	153	(28.1)	
University degree	207	(19.7)	92	(16-9)	
Unknown	11	(1.0)	47	(8.6)	
Time since diagnosis (months) [median (IQR)]	24	(6 - 42)	24	(6 - 42)	
Unknown (n, %)	9	(0.9)	43	(7.9)	
Tumor characteristics	n	%	n	%	
Pathological T stadium					
0	66	(6.3)	44	(8.1)	
In situ (IS)	92	(8.8)	56	(10.3)	
1	585	(55.7)	301	(55.3)	
	211	(20.1)	100	(18.4)	
	22	(2.1)	16	(2.9)	
IV	1	(0.1)	3	(0.6)	
X	23	(2.2)	7	(1.3)	
Unknown	51	(4.9)	17	(3.1)	
Pathological N stadium					
X	66	(6.3)	23	(4.2)	
0	606	(57.7)	329	(60.5)	
1	268	(25.5)	145	(26.7)	
11	25	(2.4)	10	(1.8)	
	7	(0.7)	2	(0.4)	
Unknown	79	(7.5)	35	(6.4)	
Treatment characteristics	n	%	n	%	
Type of breast surgery		-			
Breast conserving therapy	813	(77-4)	440	(80-9)	

Mastectomy	94	(8-9)	50	(9.2)
Mastectomy with direct breast reconstruction	93	(8.8)	43	(7.9)
No breast surgery	2	(0.2)	1	(0.2)
Unknown	49	(4.7)	10	(1.8)
Most invasive axillary treatment				
Sentinel node procedure	784	(74.6)	420	(77-2)
Axillary lymph node dissection	82	(7.8)	40	(7.3)
Unknown or not performed	185	(17.6)	84	(15.5)
Systemic therapy ²				
No systemic therapy	206	(19.6)	169	(31.1)
Chemotherapy	119	(11.3)	73	(13-4)
Endocrine therapy	282	(26.8)	182	(33.5)
Immunotherapy	73	(6.9)	19	(3.5)
Combination of above	49	(4.7)	63	(11.6)
Other	4	(0.4)	4	(0.7)
Unknown	318	(30-3)	34	(6-2)
Radiation therapy				
Local	678	(64.5)	361	(66-4)
Locoregional ³	244	(23.2)	141	(25.9)
Other or type unknown	42	(4.0)	6	(1.1)
No radiation therapy	17	(1.6)	8	(1.5)
Unknown	70	(6.7)	28	(5.1)

555

As a result of rounding, percentages may not add up a 100%.

557 Abbreviations: IQR; Interquartile Range, n; number, SD; Standard Deviation.

¹ Calculated as weight/height2.

559 ² Pre- and/ or postoperative therapy.

³ Including supraclavicular and/ or axillary lymph nodes.

562 **Table 2**. COVID-19 specific questions (n = 1051).

563

	Number of	Percentage
	patients	
	n	(%)
Are you currently receiving active breast cancer treatment? ¹		
Yes	51	(4.9)
No	1000	(95.1)
Are / were you infected by the COVID-19?		
Yes, confirmed by nasopharyngeal swab	1	(0.1)
Possibly, I have or had fever	100	(9.5)
No, I was tested negative	9	(0.9)
No, I had/ have no symptoms and I was not tested	941	(89.5)
Do the current COVID-19 measure affect your current treatment or (after)care?		
Yes	286	(27.2)
No	765	(72.8)
Do you expect that the current COVID-19 measures will affect your treatment or (after)care in the future?		
Yes	250	(23.8)
No	801	(76.2)
Did the threshold to contact your <u>general practitioner</u> change, because of the COVID-19 situation? Yes, I contact my general practitioner more easily	19	(1.8)
Yes, I contact my general practitioner less easily	327	(31.1)
No	705	(67.1)
	100	(07-1)
Did the threshold to contact the <u>physicians treating your</u> <u>breast cancer</u> change, because of the COVID-19 situation?		
Yes, I contact my breast cancer physician(s) more easily	8	(0.8)
Yes, I contact my breast cancer physician(s) less easily	162	(15.4)
No	881	(83.8)
Did the threshold to discuss your breast cancer diagnosis or breast cancer (treatment) related symptoms with <u>family</u> <u>and friends</u> change, because of the COVID-19 situation?		
Yes, I contact my friends and family more easily	14	(1.3)
Yes, I contact my friends and family less easily	87	(8.3)
No	950	(90-4)
Are you worried about your financial situation as a result of COVID-19?		
Not at all	663	(63-1)
A little bit	320	(30-4)
Quite a bit	53	(5.0)
Very much	15	(1.4)

564

565 As a result of rounding, percentages may not add up a 100%.

¹ Active treatment includes chemotherapy and/ or radiation therapy.

567 **Table 3.** Comparison of crude patient-reported outcomes of all patients who completed the same questionnaire during and 2 years before COVID-19 (n = 1022

	Before ¹	COVID-19	During C	COVID-19			
EORTC-QLQ30 and BR23 ²	mean	SD	mean	SD	MD	95% CI	p-value
Quality of Life (QoL)	76.3	(18.2)	78.9	(16.6)	-2.6	-3.61.6	< 0.001
Future perspectives (FP)	70.8	(24.9)	69.7	(20.0)	1.1	-0-2 - 2-4	0.086
Functioning scales							
Physical functioning (PF)	87.0	(15.1)	88.6	(14.0)	-1·5 ⁺	-2-20-9	< 0.001
Role functioning (RF)	78.3	(26.3)	81.8	(23.6)	-3.5	-5.11.9	< 0.001
Emotional functioning (EF)	82.6	(18.7)	77.9	(17.3)	4.6	3.6 - 5.6	< 0.001
Social functioning (SF)	86-8	(20.8)	88.5	(20.2)	-1.6+	-2.90.4	0.010
Cognitive functioning (CF)	80.8	(20.9)	82.2	(18.3)	-1-4	-2-40-4	0.004
Symptom scales							
Dyspnea (D)	12.0	(21.6)	10.5	(18.6)	1.5	0.3 - 2.7	0.014
Insomnia (I)	27.3	(28.3)	27.1	(26.5)	0.2	-1.5 - 1.8	0.845
Financial difficulties (FD)	6.2	(16.6)	5.9	(16.0)	0.3	-0.6 - 1.2	0.568
HADS ³	median	IQR	median	IQR		Z	p-value
Total	7	(4-11)	8	(5-12)		-6.87	< 0.001
Anxiety	4	(3-7)	4	(3-6)		-0.58	0.560
Depression	2	(1-5)	3	(2-6)		-11.60	< 0.001
Loneliness Scale ⁴			n	%			
Not lonely			546	(52.0)			
Moderately lonely			409	(38.9)			
Severely lonely			96	(9-1)			

for EORTC, and n = 942 for HADS). Loneliness score was only measured during COVID-19 (n = 1051).

569

- 571 Score, IQR; Interquartile Range, MD; Mean Difference, SD; Standard deviation.
- ¹ Last valid score measured within the last two years before start COVID-19 pandemic.

² EORTC-QLQ30 scores range from 0 to 100. Higher scores represent better outcomes for QoL, FP and functioning scales, and lower scores on symptom

574 scales indicate better outcomes.

³ A HADS total score > 7 indicates a possible anxiety disorder or depression and a score > 11 indicates a probable depression or anxiety disorder.

⁵⁷⁰ Abbreviations CI; Confidence Interval, EORTC; European Organization for Research and Treatment of Cancer, HADS; Hospital Anxiety and Depression

- ⁴ Higher scores indicate more severe feelings of loneliness.
- 577 ⁺ MD differs from difference mean scores due to rounding.

579 **Table 4**. Mixed model analyses in complete cases. The effect of COVID-19 on different EORTC¹ subdomains of quality of life per follow-up period.

580

	No active treatment							Active treatment				
	<24	<24 months follow-up 24-60 months follow-up > 60 months follow-up										
		n = 441 n = 430				n = 104			n = 47			
	Between group difference				Between group difference			Between group difference			Between group difference	
Group	Mean ²	MD	95% CI	Mean ²	MD	95% CI	Mean ²	MD	95% CI	Mean ²	MD	95% CI
Quality of Life												
Pre-COVID-19	73.3	Ref∙	71.6-75.0	79.2	Ref.	77.6-80.8	79.6	Ref.	76-2-82-9	65.5	Ref.	56-2-74-8
During COVID- 19	78.6	-5-3*	77.1-80.1	79.8	-0-6	78-3-81-4	80.0	-0-4	76.7-83.2	67.5	-2.0	60.0-75.0
Physical Functioning												
Pre-COVID-19	86.9	Ref.	85.5-88.3	88.0	Ref.	86.7-89.3	85.0	Ref.	81.6-88.4	75-2	Ref.	65.5-84.9
During COVID- 19	89-4	-2-5*	88-2-90-6	88-8	-0-8*	87.6-90.0	88.0	-3-0*	84-6-91-4	75.2	<0.01	66.5-83.9
Role Functioning												
Pre-COVID-19	73.4	Ref.	70.8-75.9	83-4	Ref.	81.3-85.5	84.1	Ref.	79.5-88.8	56.3	Ref.	38.7-74.0
During COVID- 19	81.3	-7.9*	79-2-83-4	84-3	-0-9	82.2-86.3	83.7	0.5⁺	79.0-88.4	55-6	0.8⁺	40.3-70.8
Emotional Functioning												
Pre-COVID-19	80.2	Ref.	78.3-82.0	84.6	Ref.	83.0-86.1	86-4	Ref.	82.8-90.0	75.8	Ref.	64.7-86.9
During COVID- 19	77.0	3-1*⁺	75.4-78.7	78-1	6-4**	76-6-79-7	82.2	4-2*	79.1-85.3	72.2	3.5⁺	63.8-80.7
Social Functioning												
Pre-COVID-19	83.6	Ref.	81.5-85.7	90-4	Ref.	88.8-92.0	90-1	Ref.	86-2-94-0	69.8	Ref.	55.6-84.1
During COVID- 19	87.1	-3-5*	85-3-89-0	91.9	-1·6 ⁺	90-4-93-5	92.0	-1-9	88-2-95-8	54.0	15 · 9* ⁺	40.6-67.4
Insomnia												
Pre-COVID-19	28.8	Ref.	26.1-31.5	26.6	Ref.	24.0-29.2	21.2	Ref.	15.9-26.4	39.7	Ref.	25.0-54.3
During COVID19	28.0	0.8	25.5-30.5	26.6	<0.01	24.1-29.0	23.4	-2.2	19.0-27.8	33-3	6.3⁺	21.9-44.8

581

582 Abbreviations CI; Confidence Interval, MD; Mean Difference, i.e. difference in mean scores between pre-COVID and during COVID19. Ref.; reference group.

¹ EORTC QLQ C30 scores range from 0-100. For quality of life, and functioning scales a higher score indicates a better outcome. For insomnia a lower score

584 indicates a better outcome.

- ² Mean scores were adjusted for age (linear). In addition, active treatment scores were adjusted for chemotherapy, type of radiotherapy and type of surger
- 586 * Significant difference with a p-value < 0.05.
- 587 ⁺ MD differs from difference mean scores due to rounding.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 1. Flowchart of inclusion of study participants from UMBRELLA-cohort. Participants who did not fill out the COVID-19 questionnaire completely (n=23) were considered non-responders.